Reversal of severe diuretic resistance by dexmedetomidine-associated polyuria in type 1 cardiorenal syndrome: a case report
Abstract
Background: Dexmedetomidine is a selective α2-adrenergic agonist widely used for sedation in intensive care settings. Although hypotension and bradycardia are well-recognized adverse effects, dexmedetomidine-associated polyuria is a rare and unpredictable adverse effect.
Case summary: An 84-year-old man with ischaemic dilated cardiomyopathy, permanent atrial fibrillation, type 2 diabetes mellitus, and chronic kidney disease was admitted to the Cardiac Intensive Care Unit with type 1 cardiorenal syndrome, severe systemic and pulmonary congestion, oliguria, and acute kidney injury. Despite continuous intravenous furosemide infusion, sequential nephron blockade, and dual vasoactive support with norepinephrine and dobutamine, the patient developed persistent oligo-anuria and worsening congestion. Dexmedetomidine infusion was initiated for psychomotor agitation and disorientation. Shortly thereafter, urine output abruptly increased to approximately 250 mL/h, accompanied by rapid decongestion and improvement in renal function. Following dexmedetomidine withdrawal, oliguria, congestion and renal dysfunction recurred. Rechallenge with dexmedetomidine again induced profound polyuria, with urine output peaking at 650 mL/h and a 10-kg weight loss over 48 h, allowing de-escalation of diuretic therapy and withdrawal of vasoactive support. The Naranjo score was 6, supporting a probable causal relationship.
Discussion: This case demonstrates a reproducible temporal association between dexmedetomidine administration and profound polyuria, confirmed by positive rechallenge. To our knowledge, this is the first report in which dexmedetomidine-associated polyuria was temporally associated with reversal of severe diuretic resistance and clinically meaningful decongestion in type 1 cardiorenal syndrome. Recognition of this rare adverse effect may be relevant in critically ill cardiac patients.
Related
- Machine learning predicts diuretic resistance via cardio hepato renal axis in heart failure comorbid with MASLD
- Diuretic-associated admissions to the emergency department – too hot to handle? Results from the ADRED-study
- Drug resistance reversal: an overview of real world success stories
- Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study
- Predicting diuretic response in acute heart failure: accurate forecasts, but better decisions?
BibTeX
@article{barazzetta2026reversal,
title = {{Reversal of severe diuretic resistance by dexmedetomidine-associated polyuria in type 1 cardiorenal syndrome: a case report}},
author = {Giulio Barazzetta and Stefano Vicini and Francesca Bruni and Francesca Bodega and Stefano Maggiolini},
journal = {European Heart Journal. Case Reports},
year = {2026},
month = oct,
doi = {10.1093/ehjcr/ytag787},
url = {https://doi.org/10.1093/ehjcr/ytag787},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Reversal of severe diuretic resistance by dexmedetomidine-associated polyuria in type 1 cardiorenal syndrome: a case report
AU - Giulio Barazzetta
AU - Stefano Vicini
AU - Francesca Bruni
AU - Francesca Bodega
AU - Stefano Maggiolini
PY - 2026
DA - 2026/10/30
JO - European Heart Journal. Case Reports
DO - 10.1093/ehjcr/ytag787
UR - https://doi.org/10.1093/ehjcr/ytag787
AB - Background: Dexmedetomidine is a selective α2-adrenergic agonist widely used for sedation in intensive care settings. Although hypotension and bradycardia are well-recognized adverse effects, dexmedetomidine-associated polyuria is a rare and unpredictable adverse effect. Case summary: An 84-year-old man with ischaemic dilated cardiomyopathy, permanent atrial fibrillation, type 2 diabetes mellitus, and chronic kidney disease was admitted to the Cardiac Intensive Care Unit with type 1 cardiorenal syndrome, severe systemic and pulmonary congestion, oliguria, and acute kidney injury. Despite continuous intravenous furosemide infusion, sequential nephron blockade, and dual vasoactive support with norepinephrine and dobutamine, the patient developed persistent oligo-anuria and worsening congestion. Dexmedetomidine infusion was initiated for psychomotor agitation and disorientation. Shortly thereafter, urine output abruptly increased to approximately 250 mL/h, accompanied by rapid decongestion and improvement in renal function. Following dexmedetomidine withdrawal, oliguria, congestion and renal dysfunction recurred. Rechallenge with dexmedetomidine again induced profound polyuria, with urine output peaking at 650 mL/h and a 10-kg weight loss over 48 h, allowing de-escalation of diuretic therapy and withdrawal of vasoactive support. The Naranjo score was 6, supporting a probable causal relationship. Discussion: This case demonstrates a reproducible temporal association between dexmedetomidine administration and profound polyuria, confirmed by positive rechallenge. To our knowledge, this is the first report in which dexmedetomidine-associated polyuria was temporally associated with reversal of severe diuretic resistance and clinically meaningful decongestion in type 1 cardiorenal syndrome. Recognition of this rare adverse effect may be relevant in critically ill cardiac patients.
SN - 2514-2119
ER -